Efficacy and cost-effectiveness of task-shared care for people with severe mental disorders in Ethiopia (TaSCS): a single-blind, randomised, controlled, phase 3 non-inferiority trial.
Journal
The lancet. Psychiatry
ISSN: 2215-0374
Titre abrégé: Lancet Psychiatry
Pays: England
ID NLM: 101638123
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
07
07
2021
revised:
30
08
2021
accepted:
10
09
2021
entrez:
18
12
2021
pubmed:
19
12
2021
medline:
29
12
2021
Statut:
ppublish
Résumé
There have been no trials of task-shared care (TSC) using WHO's mental health Gap Action Programme for people with severe mental disorders (psychosis or affective disorder) in low-income or middle-income countries. We aimed to evaluate the efficacy and cost-effectiveness of TSC compared with enhanced specialist mental health care in rural Ethiopia. In this single-blind, phase 3, randomised, controlled, non-inferiority trial, participants had a confirmed diagnosis of a severe mental disorder, recruited from either the community or a local outpatient psychiatric clinic. The intervention was TSC, delivered by supervised, non-physician primary health care workers trained in the mental health Gap Action Programme and working with community health workers. The active comparison group was outpatient psychiatric nurse care augmented with community lay workers (PSY). Our primary endpoint was whether TSC would be non-inferior to PSY at 12 months for the primary outcome of clinical symptom severity using the Brief Psychiatric Rating Scale, Expanded version (BPRS-E; non-inferiority margin of 6 points). Randomisation was stratified by health facility using random permuted blocks. Independent clinicians allocated groups using sealed envelopes with concealment and outcome assessors and investigators were masked. We analysed the primary outcome in the modified intention-to-treat group and safety in the per-protocol group. This trial is registered with ClinicalTrials.gov, number NCT02308956. We recruited participants between March 13, 2015 and May 21, 2016. We randomly assigned 329 participants (111 female and 218 male) who were aged 25-72 years and were predominantly of Gurage (198 [60%]), Silte (58 [18%]), and Mareko (53 [16%]) ethnicity. Five participants were found to be ineligible after randomisation, giving a modified intention-to-treat sample of 324. Of these, 12-month assessments were completed in 155 (98%) of 158 in the TSC group and in 158 (95%) of 166 in the PSY group. For the primary outcome, there was no evidence of inferiority of TSC compared with PSY. The mean BPRS-E score was 27·7 (SD 4·7) for TSC and 27·8 (SD 4·6) for PSY, with an adjusted mean difference of 0·06 (90% CI -0·80 to 0·89). Per-protocol analyses (n=291) were similar. There were 47 serious adverse events (18 in the TSC group, 29 in the PSY group), affecting 28 participants. These included 17 episodes of perpetrated violence and seven episodes of violent victimisation leading to injury, ten suicide attempts, six hospital admissions for physical health conditions, four psychiatric admissions, and three deaths (one in the TSC group, two in the PSY group). The incremental cost-effectiveness ratio for TSC indicated lower cost of -US$299·82 (95% CI -454·95 to -144·69) per unit increase in BPRS-E scores from a health care sector perspective at 12 months. WHO's mental health Gap Action Programme for people with severe mental disorders is as cost-effective as existing specialist models of care and can be implemented effectively and safely by supervised non-specialists in resource-poor settings. US National Institute of Mental Health.
Sections du résumé
BACKGROUND
There have been no trials of task-shared care (TSC) using WHO's mental health Gap Action Programme for people with severe mental disorders (psychosis or affective disorder) in low-income or middle-income countries. We aimed to evaluate the efficacy and cost-effectiveness of TSC compared with enhanced specialist mental health care in rural Ethiopia.
METHODS
In this single-blind, phase 3, randomised, controlled, non-inferiority trial, participants had a confirmed diagnosis of a severe mental disorder, recruited from either the community or a local outpatient psychiatric clinic. The intervention was TSC, delivered by supervised, non-physician primary health care workers trained in the mental health Gap Action Programme and working with community health workers. The active comparison group was outpatient psychiatric nurse care augmented with community lay workers (PSY). Our primary endpoint was whether TSC would be non-inferior to PSY at 12 months for the primary outcome of clinical symptom severity using the Brief Psychiatric Rating Scale, Expanded version (BPRS-E; non-inferiority margin of 6 points). Randomisation was stratified by health facility using random permuted blocks. Independent clinicians allocated groups using sealed envelopes with concealment and outcome assessors and investigators were masked. We analysed the primary outcome in the modified intention-to-treat group and safety in the per-protocol group. This trial is registered with ClinicalTrials.gov, number NCT02308956.
FINDINGS
We recruited participants between March 13, 2015 and May 21, 2016. We randomly assigned 329 participants (111 female and 218 male) who were aged 25-72 years and were predominantly of Gurage (198 [60%]), Silte (58 [18%]), and Mareko (53 [16%]) ethnicity. Five participants were found to be ineligible after randomisation, giving a modified intention-to-treat sample of 324. Of these, 12-month assessments were completed in 155 (98%) of 158 in the TSC group and in 158 (95%) of 166 in the PSY group. For the primary outcome, there was no evidence of inferiority of TSC compared with PSY. The mean BPRS-E score was 27·7 (SD 4·7) for TSC and 27·8 (SD 4·6) for PSY, with an adjusted mean difference of 0·06 (90% CI -0·80 to 0·89). Per-protocol analyses (n=291) were similar. There were 47 serious adverse events (18 in the TSC group, 29 in the PSY group), affecting 28 participants. These included 17 episodes of perpetrated violence and seven episodes of violent victimisation leading to injury, ten suicide attempts, six hospital admissions for physical health conditions, four psychiatric admissions, and three deaths (one in the TSC group, two in the PSY group). The incremental cost-effectiveness ratio for TSC indicated lower cost of -US$299·82 (95% CI -454·95 to -144·69) per unit increase in BPRS-E scores from a health care sector perspective at 12 months.
INTERPRETATION
WHO's mental health Gap Action Programme for people with severe mental disorders is as cost-effective as existing specialist models of care and can be implemented effectively and safely by supervised non-specialists in resource-poor settings.
FUNDING
US National Institute of Mental Health.
Identifiants
pubmed: 34921796
pii: S2215-0366(21)00384-9
doi: 10.1016/S2215-0366(21)00384-9
pmc: PMC8872807
mid: NIHMS1766484
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02308956']
Types de publication
Clinical Trial, Phase III
Equivalence Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-71Subventions
Organisme : Medical Research Council
ID : MR/M025470/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : R34 MH106645
Pays : United States
Organisme : NIMH NIH HHS
ID : U19 MH095699
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
Lancet. 2011 Nov 5;378(9803):1664-75
pubmed: 22008426
BJPsych Open. 2019 Apr 08;5(3):e34
pubmed: 31530317
PLoS Med. 2019 Feb 14;16(2):e1002748
pubmed: 30763321
Lancet. 2020 Aug 29;396(10251):612-622
pubmed: 32861306
Health Policy Plan. 2020 Jun 1;35(5):567-576
pubmed: 32150273
Evid Based Ment Health. 2021 Apr 26;:
pubmed: 33903119
BMC Psychiatry. 2016 Sep 07;16(1):311
pubmed: 27604273
Cochrane Database Syst Rev. 2013 Nov 19;(11):CD009149
pubmed: 24249541
Arch Gen Psychiatry. 1988 Dec;45(12):1069-77
pubmed: 2848472
Schizophr Res. 2000 Mar 16;42(1):67-77
pubmed: 10706987
Epidemiol Psychiatr Sci. 2019 Aug 13;29:e45
pubmed: 31405401
Schizophr Bull. 1986;12(4):578-602
pubmed: 3810065
Schizophr Bull. 2007 Jan;33(1):192-9
pubmed: 16894025
J Nerv Ment Dis. 1993 Sep;181(9):552-7
pubmed: 8245923
Br J Psychiatry. 2015 Apr;206(4):289-96
pubmed: 25657358
Trials. 2016 Feb 11;17:76
pubmed: 26865254
Alcohol Alcohol. 2002 Jan-Feb;37(1):61-6
pubmed: 11825859
J Psychiatr Pract. 2001 Jan;7(1):41-7
pubmed: 15990500
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Schizophr Bull. 2009 May;35(3):646-54
pubmed: 18448478
Int J Ment Health Syst. 2019 Sep 30;13:63
pubmed: 31583013
Am J Public Health. 2002 Jan;92(1):92-8
pubmed: 11772769
J Psychiatr Res. 2016 Oct;81:140-51
pubmed: 27451107
Soc Psychiatry Psychiatr Epidemiol. 1996 Mar;31(2):55-69
pubmed: 8881086
Lancet Psychiatry. 2019 Feb;6(2):174-186
pubmed: 30449711
Health Policy Plan. 2016 Apr;31(3):367-76
pubmed: 26282860
Int J Methods Psychiatr Res. 2021 Sep;30(3):e1886
pubmed: 34245195
Br J Psychiatry. 1999 Aug;175:180-5
pubmed: 10627803
BMC Health Serv Res. 2017 Mar 9;17(1):183
pubmed: 28274231
PLoS One. 2020 Feb 21;15(2):e0228854
pubmed: 32084663
Health Qual Life Outcomes. 2017 Apr 5;15(1):64
pubmed: 28381230
Gen Hosp Psychiatry. 2019 Jul - Aug;59:20-29
pubmed: 31096165